Beatrix Bálint

Suggest Changes
Learn More
BACKGROUND Necitumumab is a second-generation, recombinant, human immunoglobulin G1 EGFR antibody. In this study, we aimed to compare treatment with necitumumab plus gemcitabine and cisplatin versus(More)
OBJECTIVES The inhaled corticosteroid fluticasone propionate (fluticasone) and the long-acting β₂ agonist formoterol fumarate (formoterol) have been combined in a single aerosol inhaler(More)
BACKGROUND Necitumumab is a second-generation recombinant human immunoglobulin G1 EGFR monoclonal antibody that competitively inhibits ligand binding. We aimed to compare necitumumab plus pemetrexed(More)
7297 Background: Adjuvant chemotherapy treatment for early stage NSCLC patients is not yet standard practice. The aim of the present trial is to compare the activity, safety, and quality of life(More)